Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm

American Journal of Cardiology

Volumn 81, Issue 6 A, 1998, Pages

  Singh, Bramah N ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ALINIDINE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BRETYLIUM; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; LIDOCAINE; MORACIZINE; NADOLOL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TEDISAMIL; TOCAINIDE; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; POTASSIUM CURRENT; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE;

EID: 0032546405     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00147-7     Document Type: Article

References (75)

1. Singh BN. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 6:1995;887-900.
2. Singh BN. Controlling cardiac arrhythmia an overview in a historical perspective . Am J Cardiol. 80:(8A):1997;4G-16G.
3. Weidmann S. Effects of calcium ions and local anesthetics on the electrical properties of Purkinje fibers. J Physiol. 129:1956;1066-1077.
4. Hoffman BF, Cranefield PF. Electrophysiology of the Heart. 1964;1-307 McGraw-Hill, New York.
5. Johnson EA, McKinnon MG. The differential effects of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharmacol Exp Ther. 120:1957;460-468.
6. Jervell A, Lang-Nielsen L. Congenital deaf-mutism, functional heart disease with the prolongation of QT interval, and sudden death. Am Heart J. 54:1957;59-68.
7. Selzer A, Wray HW. Quinidine syncope paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias . Circulation. 30:1964;17-26.
8. Dessertenne F. La tachycardia ventriculaire a deux foyers oppose variables. Arch Mal Coeur. 59:1966;263-272.
9. Singh BN, Vaughan Williams EM. Effects of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res. 29:1971;286-295.
10. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction . N Engl J Med. 321:1989;406-412.
11. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
12. Singh BN. Pharmacological actions of certain cardiac drugs and hormones: focus on antiarrhythmic mechanisms. PhD Thesis, 1971. Hertford College and University of Oxford, England. Mt Kisco, NY: Futura Publishing, 1991:1-98.
13. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474 . Br J Pharmacol. 39:1970;675-687.
14. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
15. Vaughan Williams EM. Classification of antiarrhythmic drugs. Sandoe E, Flenstedt-Jensen E, Olesen KH. Symposium on Cardiac Arrhythmias. 1970;440-469 AB Astra, Sodertalje, Sweden.
16. Singh BN, Vaughan Williams EM. A fourth class of antidysrhythmic action effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function . Cardiovasc Res. 6:1972;109-119.
17. Nattel S. Antiarrhythmic drug classifications a critical appraisal of their history, present status, and clinical relevance . Drugs. 41:1991;672-701.
18. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 87:1974;367-377.
19. Harrison DC. Is there a rational basis for the modified classification of antiarrhythmic drugs? Morganroth J, Moore EN. Cardiac Arrhythmias New Therapeutic Drugs and Devices . 1985;36-48 Martinus Nijhoff, Boston.
20. Campbell JC. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 17:1983;344-352.
21. Heng MK, Singh BN, Roche AHG, Norris RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 90:1975;487-578.
22. Yusuf S, Teo KK. Approaches and prevention of sudden death need for fundamental reevaluation . J Cardiovasc Electrophysiol. 2:1991;5233-5239.
23. The Sicilian Gambit a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms . Circulation. 84:1991;1831-1851.
24. Singh BN. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol 1996;78(suppl 4A):17-27.
25. Rosen MR. Cardiac arrhythmias and antiarrhythmic drugs recent advances in our understanding of mechanisms . J Cardiovasc Electrophysiol. 6:1995;868-879.
26. Ahmed R, Singh BN. Anti-arrhythmic drugs. Curr Opin Cardiol. 8:1993;10-21.
27. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol. 9:1994;12-22.
28. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 68:1991;1025-1031.
29. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion a meta-analysis of randomized controlled trials . Circulation. 82:1990;1106-1116.
30. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 20:1992;427-532.
31. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias a meta-analysis . Circulation. 84:1991;1977-1983.
32. Schwartz PJ. The idiopathic long QT interval syndrome progress and questions . Am Heart J. 109:1985;399-405.
33. Steinbeck G, Andersen D, Bach P, Haberi R, Oeff M, Hoffman E, Von Leitner ER. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med. 327:1992;987-993.
34. Yusuf S, Peto R, Lewis J, Sleight P. Beta-blockade during myocardial infarction an overview of randomized trials . Prog Cardiovasc Dis. 27:1985;335-355.
35. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the PRECISE trial . Circulation. 94:1996;2793-2801.
36. A randomized trial of beta-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
37. Singh BN. Control of cardiac arrhythmias with sotalol, a broad-spectrum anti-arrhythmic with beta-blocking effects and Class III activity. Am J Cardiol. 76:(suppl):1990;1A-84A.
38. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 35:1997;13-29.
39. Mason JW. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;445-451.
40. The CASCADE Study randomized anti-arrhythmic drug therapy in survivors of cardiac arrest in Seattle . Am J Cardiol. 72:1993;280-287.
41. Wever EF, Hauer RNW, Van Capelle FJL. Randomized study of implantable defibrillator as first-choice versus conventional strategy in post-infarct sudden death survivors. Circulation. 91:1995;2195-2203.
42. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias . Circulation. 82:1990;2235-2242.
43. Kato R, Ikeda N, Yabek SM, Kannan R, Singh BN. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol. 7:1986;116-125.
44. Singh BN. Choice and chance in drug therapy of cardiac arrhythmias technique versus drug-specific responses in evaluation of efficacy . Am J Cardiol. 72:1993;114-124.
45. Singh BN. Arrhythmia control by prolonging repolarization the concept and its potential therapeutic impact . Eur Heart J. 14:1993;14-23.
46. Papp JG, Nemeth M, Krassoi I, Mester L, Hala O, Varro A. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Ther. 1:1996;187-196.
47. Sicouri S, Moro S, Litovsky S, Elizari M, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 8:1997;1280-1290.
48. Cui G, Sen L, Sager PT, Uppal P, Singh BN. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol. 75:1995;465-469.
49. Sager PT, Uppal P, Follmer CT, Antimisiaris M, Pruitt C, Singh BN. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 88:1993;1063-1072.
50. Takanaka C, Singh BN. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization significance of slow-channel activity and differing effects of quinidine and amiodarone . J Am Coll Cardiol. 15:1990;213-221.
51. Hohnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects a review with special reference to torsades de pointes tachycardia . Ann Intern Med. 121:1994;529-535.
52. Kowey PR, Levine JH, Pacifico A, Lindsay BD, Plumb VJ, for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 1995;92:3255-3263.
53. Scheinman MM, Levine JH, Cannom DS, Kopelman FT, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-3272.
54. Nasir N, Swarna US, Boahene KA, Doyle TK, Pacifico A. Therapy of sustained ventricular arrhythmias with amiodarone prediction of efficacy with serial electrophysiologic studies . J Cardiovasc Pharmacol Ther. 1:1996;123-133.
55. Fermini B, Jurkiewicz NK, Jow B. Use-dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block of delayed rectifier potassium and L-type calcium currents . J Cardiovasc Pharmacol. 26:1995;259-271.
56. Falk RH, Pollak A, Singh SN, Friederich T, for Dofetilide Investigators. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385-390.
57. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
58. Singh BN. Acute conversion of atrial flutter and fibrillation direct current cardioversion versus intravenously administered pure class III agents . J Am Coll Cardiol. 29:1997;391-393.
59. Singh BN, Wellens HJJ, Hiraoka M. Electropharmacological Control of Cardiac Arrhythmias To Delay Conduction or to Prolong Refractoriness? 1994;1-713 Futura Publishing, Mt. Kisco, New York.
60. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of cardiac repolarization theoretical considerations and clinical observations . Am Heart J. 109:1985;421-430.
61. Roden DM. Ibutilide and the treatment of atrial arrhythmias a new drug-almost unheralded-is now available to US physicians . Circulation. 94:1996;1499-1502.
62. Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effects of d-sotalol on mortality in patients with left ventricular function after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
63. Danish Trial in Acute Myocardial Infarction on Dofetilide (DIAMOND). Preliminary results presented at the European Congress of Cardiology. Stockholm, August, 1997.
64. Nemeth M, Varro A, Virag L, Hala O, Thormahlen D, Papp JG. Frequency dependent cardiac electrophysiological effects of tedisamil comparison with quinidine and sotalol . J Cardiovasc Pharmacol Ther. 2:(4):1997;273-284.
65. Tsuchihashi K, Curtis MJ. Tedisamil possesses direct defibrillatory activity during myocardial ischemia and during reperfusion. (Abstr.). Br J Pharmacol. 99:1990;231P.
66. to). (Abstr.). Circulation. 82:(suppl III):1991;III-452.
67. + channels in rat and guinea pig ventricular myocytes. Am J Physiol. 257:1989;H1746-H1749.
68. +-currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther. 254:1990;560-569.
69. Friedrichs GS, Abreu JN, Cousins GR, Chi L, Borlak J, Lucchesi BR. Tedisamil attenuates ventricular fibrillation in a conscious canine model of sudden cardiac death. J Cardiovasc Pharmacol Ther. 1:1996;313-324.
70. Lamorgese M, Kirian M, Van Wagoner DR. Azimilide (NE-10064) blocks outward K currents in human atrial and ventricular myocytes. (Abstr.). Circulation. 92:(suppl 8):1997;I-575.
71. Restivo M, Hegazy M, El-Hamamy M, et al. Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. (Abstr.). Pacing Clin Electrophysiol. 19:1996;664.
72. Drexler AP, Micklas JM, Brooks RR. Effects of intravenously administered NE-10064 on programmed electrical stimulation (PES)-induced ventricular arrhythmias in anesthetized infarcted dogs. (Abstr.). FASEB J. 7:1993;A97.
73. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol. 22:1993;810-818.
74. Corey AE, Al-Khalidi H, Brezovic C, Marcello SR, Parekh N, Taylor K, Karam R. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. (Abstr.). Clin Pharmacol Ther. 61:1997;205.
75. Agnew J, Comer PF, Corey AE, Griffith SG, Li J, Bao J. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. (Abstr.). Pharmacol Res. 13:(suppl 9):1996;S-429.